COMBI-d: Phase 3 trial of dabrafenib plus trametinib in BRAF V600E/K-mutated melanoma - European Medical Journal
×

Browse

COMBI-d: Phase 3 trial of dabrafenib plus trametinib in BRAF V600E/K-mutated melanoma

|
Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Georgina Long, BSc, PhD, MBBS, FRACP, of the University of Sydney, Sydney, Australia, discusses the results of the randomised, double-blinded, phase 3 COMBI-d trial, which compared the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) versus dabrafenib and placebo as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma.